Sep 09, 2020 / 03:40PM GMT
Andrew Simon Baum - Citigroup Inc., Research Division - Global Head of Healthcare Research and MD
Welcome back. Delighted to introduce our next session today. We have Hal Barron, the Chief Scientific Officer at GSK. We've got Jeff McLaughlin and other members of the GSK Investor Relation team. Pleasure to have you with us, Hal.
Questions and Answers:
Andrew Simon Baum - Citigroup Inc., Research Division - Global Head of Healthcare Research and MDSo look, I'm looking forward to a broad-ranging conversation. Given GSK is one of the preeminent vaccine manufacturers in the world and given we had news overnight of the suspension of one of your competitors' Phase III trial programs for COVID, as a way of segmenting into your COVID efforts, perhaps you can talk to how you would see the hurdle for safety to COVID. And I guess, general concept, because, obviously, we don't know the details and there's been some information that trial may restart. How many episodes of demyelination associated with a vaccine in a patient without preexisting conditions is enough to
Trustpilot
